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Background: Ultrafiltration (UF) is used to treat patients with diuretic-resistant, decompensated heart failure (HF); however worsening renal 
function (WRF) is a common complication. The aim of this study was to identify the clinical, laboratory, and echocardiographic predictors of WRF 
during UF.
Methods: From 1/2008 to 7/2010, 60 patients (age 68±13 years, 57% men) underwent UF at the University of Nebraska Medical Center. All 
patients were on optimal HF medical therapy. Average intravenous dose of furosemide before UF was 217±209 mg/day. WRF was defined as a rise in 
serum creatinine level > 0.3 mg/dl. Patients were divided into WRF and control groups based on changes in serum creatinine during UF.
Results: In the whole study population, BUN increased from 51.2±22.3 mg/dL to 59.1±26.8 mg/dL (p < 0.001), creatinine increased from 
1.9±0.2 mg/dL to 2.2 ± 0.9 mg/dL, (p=0.002) and WRF developed in 25 (42%) of patients.
Female gender (15 (60%) vs. 11 (31%), p=0.03) and treatment with spironolactone (8(32%) vs. 2(6%), p=0.007) were associated with increased 
risk of WRF in univariate analysis. There was no difference between groups in baseline demographic, laboratory, and hemodynamic characteristics.
Echocardiography at admission showed smaller left ventricular end diastolic volume (LVEDV: 121 ± 49mL vs.152 ± 56mL, p=0.04), larger right 
ventricular diameter (RVD: 42.3±6.2 mm vs. 38.4 ± 7.5mm, p=0.05), and lower E’ (5.6 ± 1.6 m/s vs. 7.2 ± 2.4 m/s, p=0.01) in the WRF group.
Peak UF rate (174 ± 51mL/h vs. 146 ± 50mL/h, p= 0.04) was higher in the WRF group, however duration of UF and change in patients weight were 
comparable.
After multivariate analysis, peak UF rate ≥ 150 mL/h (OR 2.36, CI 1.06 - 4.82, p=0.04), RVD (OR 1.1, CI 1.01 - 1.86, p=0.04), LVEDV (OR 0.88, CI 
0.75 - 0.98, p=0.012), and E’ (OR 1.6, CI 1.13 - 2.93, p=0.005) were independently associated with higher risk of WRF during UF.
Conclusions: WRF occurred frequently in patients treated with UF. Cardiac remodeling indices on echocardiography at hospital admission can 
identify patients at increased risk for developing WRF. UF rate > 150 mL/h was associated with increased risk of WRF. The role of spironolactone in 
WRF during UF deserves further evaluation.
